A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.

• Sponsor: Jazz Pharmaceuticals (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00711880
• Collaborator: (none)
• Enrollment: 125
• Location: 1
• Arms: 2
• Duration (Months): 22
• Patients Per Site Per Month: 5.7

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.

Condition or Disease	Intervention/Treatment	Phase
Pain; Peripheral Neuropathy	Drug: Sativex®; Drug: Placebo	Phase 3

Detailed Description

This was a six week, multicentre, double blind, randomised, placebo controlled parallel group study to evaluate the efficacy of Sativex®. Subjects with peripheral neuropathic pain characterised by allodynia, were screened to determine eligibility and entered a seven day baseline period. Subjects then returned to the centre for randomisation and dose introduction, and received either placebo or Sativex in a double blind manner for five weeks, with a follow up visit 7 to 10 days after the end of the treatment period. The primary efficacy measure was the difference in pain severity at the end of treatment, measured using a peripheral neuropathic pain 0 to 10 numerical rating scale.

Study Design

• Study Type: Interventional
• Actual Enrollment: 125 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Supportive Care
• Official Title: A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.
• Study Start Date: May 1, 2002
• Actual Primary Completion Date: Mar 1, 2004
• Actual Study Completion Date: Mar 1, 2004

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sativex	Drug: Sativex®; containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours; Other Names: GW-1000-02
Placebo Comparator: Placebo	Drug: Placebo; containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.; Other Names: GW-4001-01

Outcome Measures

Primary Outcome Measures

1. Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment) [Day 0 to Day 42]

   The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.

Secondary Outcome Measures

1. Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment [Day 0 to Day 42]

   The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.

2. Change From Baseline in Mean Sleep Quality at the End of Treatment [Day 7 - Day 42]

   The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.

3. Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment [Day 0 - Day 42]

   The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.

4. Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment [Day 7 and Day 42]

   Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.

5. Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment [Day 0 - Day 42]

   The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.

6. Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment [Day 7 and Day 42]

   The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.

7. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment [Day 7 and Day 42]

   The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.

8. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment [Day 7 and Day 42]

   The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.

9. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment [Day 7 and Day 42]

   The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.

10. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment [Day 7 and Day 42]

    The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive

11. Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment [Day 7 and Day 42]

    Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).

12. Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment [Day 42]

    Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.

13. Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment [Day 0 - Day 42]

    Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.

14. Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment [Day 0 - 42]

    Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects

15. Incidence of Adverse Events as a Measure of Subject Safety [Day 0 - Day 42]

    The number of subjects who reported an adverse event during the course of the study is presented

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Willing and able to give informed consent.

• Male or female, aged 18 years or above.

• Chronic peripheral neuropathic pain of at least six months duration.

• Presence of mechanical allodynia within the territory of the affected nerve(s).

• Evidence of sensory change in the affected nerve by simple clinical tests.

• Peripheral neuropathic pain with a severity score of four or more on at least four completed NRS during the baseline week.

• Stable dose of analgesic medication for at least two weeks leading to study entry.

• Agreement, if female and of child bearing potential or if male with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter.

• Have not used cannabinoids (including cannabis, Marinol or Nabilone) for at least seven days before Visit 1 and were willing to abstain from any use of cannabinoids during the study.

• Ability (in the investigator's opinion) and willingness to comply with all study requirements.

• Agreement for the UK Home Office, their primary care physician, and their consultant if appropriate, to be notified of their participation in the study.

Exclusion Criteria:

• History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.

• Concomitant severe non-neuropathic pain or the presence of cancer related neuropathic pain or neuropathic pain resulting from diabetes mellitus.

• Known history of alcohol or substance abuse.

• Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure.

• History of epilepsy.

• If female, were pregnant or lactating, or were planning a pregnancy to occur during the course of the study.

• Significant renal or hepatic impairment.

• Elective surgery or other procedures requiring general anaesthesia scheduled to occur during the study.

• Terminal illness or were considered inappropriate for placebo medication.

• Any other significant disease or disorder which, in the opinion of the investigator, may have either put the subject at risk because of participation in the study, or may influenced the result of the study, or the subject's ability to participate in the study.

• Regular levodopa (Sinemet®, Sinement Plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®) therapy within the seven days leading to study entry.

• If male, were receiving and were unwilling to stop sildenafil (Viagra®) for the duration of the study.

• Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medications.

• Known or suspected adverse reaction to cannabinoids.

• Intention to travel internationally during the study.

• Intention to donate blood during the study.

• Participation in another research study in the 12 weeks leading to study entry.

• Previous randomisation into this study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Clinical Trials Unit, The Walton Centre	Fazakerley	Liverpool	United Kingdom	L9 7LJ

Sponsors and Collaborators

• Jazz Pharmaceuticals

Investigators

• Principal Investigator: Turo Nurmikko, MB BS PhD, Clinical Trials Unit, The Walton Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jazz Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT00711880
• Other Study ID Numbers: GWNP0101
• First Posted: Jul 9, 2008
• Last Update Posted: Feb 24, 2021
• Last Verified: Feb 1, 2021

• Keywords provided by Jazz Pharmaceuticals: Pain; Peripheral Neuropathy
• Additional relevant MeSH terms: Neuralgia; Peripheral Nervous System Diseases; Hyperalgesia; Nabiximols

Study Results

Participant Flow

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Period Title: Overall Study
STARTED	63	62
COMPLETED	50	55
NOT COMPLETED	13	7

Baseline Characteristics

Arm/Group Title	Sativex	Placebo	Total
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.	Total of all reporting groups
Overall Participants	63	62	125
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	51 81%	49 79%	100 80%
>=65 years	12 19%	13 21%	25 20%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	52.4 (15.8)	54.3 (15.2)	53.4 (15.4)
Sex: Female, Male (Count of Participants)
Female	35 55.6%	39 62.9%	74 59.2%
Male	28 44.4%	23 37.1%	51 40.8%
Region of Enrollment (participants) [Number]
United Kingdom	51 81%	50 80.6%	101 80.8%
Belgium	12 19%	12 19.4%	24 19.2%

Outcome Measures

1. Primary Outcome

Title	Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)
Description	The neuropathic pain Numerical Rating Scale was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = worst possible pain. A negative value indicates an improvement in pain score from baseline.
Time Frame	Day 0 to Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	61	62
Mean (Standard Deviation) [units on a scale]	-1.57 (2.11)	-0.59 (1.38)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in Numerical Rating Scale Peripheral Neuropathic Pain scores was compared between treatment groups using analysis of covariance (ANCOVA). The model included treatment and centre as factors and baseline Numerical Rating Scale Peripheral Neuropathic Pain score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.004
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-0.96
	Confidence Interval	(2-Sided) 95%; -1.59 to -0.32
	Parameter Dispersion	Type: Value:
	Estimation Comments

2. Secondary Outcome

Title	Change From Baseline in Mean Neuropathic Pain Scale Score at the End of Treatment
Description	The Neuropathic Pain Scale (NPS) score consisted of a series of assessments of different aspects of pain (intensity, sharpness, hot, dull, cold, sensitive, itchy, unpleasantness, and surface compared with deep), each scored using 11-point Numerical Rating Scales. The NPS score is 0-100 sum of 10 individual pain scores (0-10 NRS, 0= no pain to 10 = most pain imaginable). A negative change from baseline indicates an improvement in pain.
Time Frame	Day 0 to Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	59	62
Mean (Standard Deviation) [units on a scale]	-9.7 (19.35)	-2.0 (12.14)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in Neuropathic Pain Scale scores was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and baseline Neuropathic Pain Scale score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.007
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-8.03
	Confidence Interval	(2-Sided) 95%; -13.83 to -2.23
	Parameter Dispersion	Type: Value:
	Estimation Comments

3. Secondary Outcome

Title	Change From Baseline in Mean Sleep Quality at the End of Treatment
Description	The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
Time Frame	Day 7 - Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	61	62
Mean (Standard Deviation) [units on a scale]	-0.82 (0.76)	-0.38 (0.68)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in sleep disturbance scores was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline sleep disturbance score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-0.43
	Confidence Interval	(2-Sided) 95%; -0.67 to -0.19
	Parameter Dispersion	Type: Value:
	Estimation Comments

4. Secondary Outcome

Title	Change From Baseline in the Mean Pain Disability Index Score at the End of Treatment
Description	The Pain Disability Index consisted of seven self-administered questions relating to the effect of the subject's chronic pain on their personal life (family/home responsibilities, social activity, sexual behaviour, life-support activity, recreation, occupation and self-care). Each assessment was scored on an 11-point Numerical Rating Scale ranging from 0 (which equals 'no disability') to 10 (which equals 'total disability'). The total Pain Disability Index is the unweighted sum of the seven Numerical Rating Scale scores. The maximum (worst) total score was 70.
Time Frame	Day 0 - Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	53	57
Mean (Standard Deviation) [units on a scale]	-5.6 (12.08)	0.3 (8.71)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in total Pain Disability Index scores was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline total Pain Disability Index score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.003
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-5.85
	Confidence Interval	(2-Sided) 95%; -9.62 to -2.09
	Parameter Dispersion	Type: Value:
	Estimation Comments

5. Secondary Outcome

Title	Change From Baseline in Mean Dynamic Allodynia Test Score at the End of Treatment
Description	Dynamic allodynia was assessed by stroking the skin over the affected area five times with a standardised brush, designed specifically for sensory testing at 5sec intervals, and recording the pain severity on a 0-10 point scale (0= no pain to 10 = most pain imaginable). All strokes were of the same length, minimum 2 cm. Each dynamic allodynia score was calculated as the average of the five strokes. A negative change from baseline indicates an improvement in score.
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	55	51
Mean (Standard Deviation) [units on a scale]	-1.15 (2.23)	-0.38 (1.72)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in Dynamic Allodynia Test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline Dynamic Allodynia Test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.042
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-0.82
	Confidence Interval	(2-Sided) 95%; -1.60 to -0.03
	Parameter Dispersion	Type: Value:
	Estimation Comments

6. Secondary Outcome

Title	Change From Baseline in Mean Static Allodynia Test Score at the End of Treatment
Description	The static allodynia test involved applying pressure to a non-allodynic area (on the contralateral side to the identified allodynic area), and recording the pressure that caused pain to this area. Seventy five percent of the pressure that caused pain to the non-allodynic area (up to the subject's pain/pressure threshold) was then applied to the allodynic area, and an 11-point Numerical Rating Scale pain score recorded (between 0 (no pain)and 10 (most intense pain imaginable)). A negative value indicates an improvement in pain score from baseline.
Time Frame	Day 0 - Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	56	62
Mean (Standard Deviation) [units on a scale]	18.22 (50.20)	2.84 (44.43)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in Static Allodynia Test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline Static Allodynia Test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.144
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	12.73
	Confidence Interval	(2-Sided) 95%; -4.40 to 29.85
	Parameter Dispersion	Type: Value:
	Estimation Comments

7. Secondary Outcome

Title	Change From Baseline in Mean Total General Health Questionnaire Score at the End of Treatment
Description	The General Health Questionnaire-12 is designed to measure non-psychotic mental disorders. It consists of 12 questions, scored on a 0 to 3 Likert scale to measure and compare psychological morbidity levels, where 0 represents better psychological health. The total General Health Questionnaire-12 score is the unweighted sum of the 12 scores. Zero indicates the best possible psychological health, 36 indicates the worst possible psychological health.
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	60	62
Mean (Standard Deviation) [units on a scale]	-3.0 (7.93)	-2.6 (5.72)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in total General Health Questionnaire score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline total General Health Questionnaire score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.483
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-0.75
	Confidence Interval	(2-Sided) 95%; -2.84 to 1.35
	Parameter Dispersion	Type: Value:
	Estimation Comments

8. Secondary Outcome

Title	Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Selective Reminding' at the End of Treatment
Description	The Selective Reminding Test measures verbal learning and delayed recall through a multiple-trial list-learning paradigm. Patients are presented aurally with a list of 12 words for trial 1 and are asked to recall as many as possible. For trials 2-6, there is a selective presentation of only those words not recalled on the previous trial. Trial 7 is similar to the other trials but is assessed after an 11-minute delay. The score for the selective reminding test is the unweighted average of seven individual study results (min=0 and max=84) Higher scores indicate a better cognitive performance.
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	40	42
Mean (Standard Deviation) [units on a scale]	0.53 (1.10)	0.48 (1.27)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in selective reminding test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline selective reminding test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.924
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	0.02
	Confidence Interval	(2-Sided) 95%; -0.46 to 0.50
	Parameter Dispersion	Type: Value:
	Estimation Comments

9. Secondary Outcome

Title	Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for '10/36 Spatial Recall' at the End of Treatment
Description	The 10/36 Spatial Recall Test assesses visual spatial learning and delayed recall. Patients are asked to view a 6 x 6 checkerboard with ten checkers for 10 seconds. They are then asked to recreate the pattern viewed on a blank checkerboard. The number of correct responses from three immediate trials and one delayed trial (7 minute delay) are recorded. The Total number of correct responses is the unweighted sum from the four trials. The score for the 10/36 spatial recall test was the unweighted average of four individual study results (min=0 and max=40). A higher score indicates better cognitive performance.
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	39	42
Mean (Standard Deviation) [units on a scale]	0.79 (2.01)	0.15 (2.12)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in 10/36 spatial recall test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline 10/36 spatial recall test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.214
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	0.53
	Confidence Interval	(2-Sided) 95%; -0.31 to 1.38
	Parameter Dispersion	Type: Value:
	Estimation Comments

10. Secondary Outcome

Title	Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Symbol Digit Modalities' at the End of Treatment
Description	The Symbol Digit Modalities Test measures complex attention and concentration in a task which also requires speed and accuracy in visual search and scanning. Patients are required to associate symbols with numbers and quickly generate the number when shown the symbol. The summary endpoint is the number of correct responses in 90 seconds. The symbol digit modalities test had a min of 0 and max score of 99. A higher score indicates better cognitive performance.
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	39	42
Mean (Standard Deviation) [units on a scale]	1.6 (5.83)	3.9 (7.38)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in symbol digit modalities test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline symbol digit modalities test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.158
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-2.15
	Confidence Interval	(2-Sided) 95%; -5.15 to 0.85
	Parameter Dispersion	Type: Value:
	Estimation Comments

11. Secondary Outcome

Title	Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Paced Auditory Serial Addition Task' at the End of Treatment
Description	The Paced Auditory Serial Addition Task assesses sustained attention and concentration. A pre-recorded tape is used to present two series of 60 numbers, one every 3 seconds and one every 2 seconds. Patients are asked to add each number to the one immediately preceding it and give the result. The task summary score is the percentage of correct answers is calculated. The PASAT score range was 0% to 100%. Higher scores indicate a better cognitive
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	24	29
Mean (Standard Deviation) [percentage of correct answers]	8.0 (14.23)	6.3 (9.25)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in paced auditory serial addition task score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline paced auditory serial addition task test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.656
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	1.28
	Confidence Interval	(2-Sided) 95%; -4.47 to 7.04
	Parameter Dispersion	Type: Value:
	Estimation Comments

12. Secondary Outcome

Title	Change From Baseline in the Mean Brief Repeatable Battery of Neuropsychological Test Score for 'Word List Generation' at the End of Treatment
Description	Word list generation measures verbal associative fluency. Patients are given 60 seconds to give as many words beginning with a particular letter. The Total is the unweighted sum of all admissible words over three different trials. Higher scores indicate a better cognitive performance (min=0, max= not defined).
Time Frame	Day 7 and Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	38	41
Mean (Standard Deviation) [number of words]	3.5 (7.67)	3.5 (8.47)

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The change in word list generation test score was compared between treatment groups using ANCOVA. The model included treatment and centre as factors and mean baseline word list generation test score as a covariate.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.962
	Comments
	Method	ANCOVA
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	-0.08
	Confidence Interval	(2-Sided) 95%; -3.56 to 3.39
	Parameter Dispersion	Type: Value:
	Estimation Comments

13. Secondary Outcome

Title	Subject Global Impression of Change in the Severity of Peripheral Neuropathic Pain at the End of Treatment
Description	Subjects were asked to give their impression of the overall change in their peripheral neuropathic pain since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. The number of subjects who reported an improvement is presented.
Time Frame	Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	63	62
Very Much Improved	5 7.9%	0 0%
Much Improved	11 17.5%	6 9.7%
Minimally Improved	16 25.4%	6 9.7%
No Change	26 41.3%	46 74.2%
Minimally Worse	0 0%	2 3.2%
Much Worse	4 6.3%	2 3.2%
Very Much Worse	0 0%	0 0%
Missing	1 1.6%	0 0%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The proportion of subjects who considered their condition 'Very Much Improved', 'Much Improved' or 'Minimally Improved' was compared between treatment groups for each question, using Fisher's Exact Test.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	<0.001
	Comments
	Method	Fisher Exact
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	32.26
	Confidence Interval	(2-Sided) 95%; 16.40 to 48.12
	Parameter Dispersion	Type: Value:
	Estimation Comments

14. Secondary Outcome

Title	Change From Pre-dose in Mean Intoxication 100 mm Visual Analogue Scale Score at the End of Treatment
Description	Intoxication scores were measured using a 100 mm Visual Analogue Scale, where 0 equalled 'no intoxication' and 100 equalled 'extreme intoxication'. A negative value indicates an improvement in intoxication score from baseline.
Time Frame	Day 0 - Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	62	62
Mean (Standard Deviation) [units on a scale]	3.2 (11.39)	1.4 (10.74)

15. Secondary Outcome

Title	Subject Global Impression of Change in the Severity of Allodynia in Their Chosen Allodynic Area at the End of Treatment
Description	Subjects were asked to give their impression of the overall change in their allodynia since entry into the study using the following seven-point scale: 1 = 'Very Much Improved', 2 = 'Much Improved', 3 = 'Minimally Improved', 4 = 'No Change', 5 = 'Minimally Worse', 6 = 'Much Worse', 7 = 'Very Much Worse'. A summary of the number and percentage of subjects
Time Frame	Day 0 - 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	63	62
Very Much Improved	3 4.8%	0 0%
Much Improved	12 19%	3 4.8%
Minimally Improved	14 22.2%	8 12.9%
No Change	30 47.6%	47 75.8%
Minimally Worse	1 1.6%	2 3.2%
Much Worse	2 3.2%	2 3.2%
Very Much Worse	0 0%	0 0%
Missing	1 1.6%	0 0%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Sativex, Placebo
	Comments	The proportion of subjects who considered their condition 'Very Much Improved', 'Much Improved' or 'Minimally Improved' was compared between treatment groups for each question, using Fisher's Exact Test.
	Type of Statistical Test	Superiority or Other (legacy)
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	Fisher Exact
	Comments
Method of Estimation	Estimation Parameter	Estimated mean treatment difference
	Estimated Value	29.03
	Confidence Interval	() 95%; 13.39 to 44.67
	Parameter Dispersion	Type: Value:
	Estimation Comments

16. Secondary Outcome

Title	Incidence of Adverse Events as a Measure of Subject Safety
Description	The number of subjects who reported an adverse event during the course of the study is presented
Time Frame	Day 0 - Day 42

Outcome Measure Data

Analysis Population Description

All randomised subjects who received at least one dose of study medication and had on-treatment efficacy data were included in the analysis

Arm/Group Title	Sativex	Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.	Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
Measure Participants	63	62
Number [participants]	57 90.5%	48 77.4%

Adverse Events

Time Frame	All adverse events occurring from the time of consent to post study follow up i.e.8 weeks were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.
Adverse Event Reporting Description	All adverse events occurring during the study were reported on the running logs at the back of the study case report form.
Arm/Group Title	Sativex		Placebo
Arm/Group Description	Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml per 100 micro litre. Maximum permitted dose was 48 actuations (THC 130 mg: CBD 120 mg) in 24 hours.		Contains no active drug but colourants and excipients. Maximum permitted dose was 48 actuations in 24 hours.
All Cause Mortality
	Sativex		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Sativex		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/63 (1.6%)		2/62 (3.2%)
General disorders
Fall	0/63 (0%)		1/62 (1.6%)
Infections and infestations
Bronchopneumonia	1/63 (1.6%)		0/62 (0%)
Nervous system disorders
Transient ischaemic attack	1/63 (1.6%)		0/62 (0%)
Hypoaesthesia	0/63 (0%)		0/62 (0%)
Myelitis NOS	0/63 (0%)		1/62 (1.6%)
Other (Not Including Serious) Adverse Events
	Sativex		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	57/63 (90.5%)		48/62 (77.4%)
Eye disorders
Vision Blurred	2/63 (3.2%)		0/62 (0%)
Gastrointestinal disorders
Nausea	14/63 (22.2%)		7/62 (11.3%)
Dry Mouth	11/63 (17.5%)		3/62 (4.8%)
Vomiting Not Otherwise Specified (NOS)	8/63 (12.7%)		3/62 (4.8%)
Diarrhoea NOS	4/63 (6.3%)		0/62 (0%)
Abdominal pain upper	3/63 (4.8%)		0/62 (0%)
Oral Pain	0/63 (0%)		2/62 (3.2%)
Dyspepsia	0/63 (0%)		2/62 (3.2%)
Constipation	2/63 (3.2%)		4/62 (6.5%)
General disorders
Fatigue	13/63 (20.6%)		5/62 (8.1%)
Feeling drunk	6/63 (9.5%)		0/62 (0%)
Fall	0/63 (0%)		3/62 (4.8%)
Lethargy	2/63 (3.2%)		0/62 (0%)
Malaise	2/63 (3.2%)		0/62 (0%)
Application Site Burning	2/63 (3.2%)		4/62 (6.5%)
Application Site Pain	4/63 (6.3%)		2/62 (3.2%)
Infections and infestations
Nasopharyngitis	4/63 (6.3%)		2/62 (3.2%)
Investigations
Blood Glucose Increased	2/63 (3.2%)		0/62 (0%)
Blood Alkaline Phosphatase NOS Increased	0/63 (0%)		2/62 (3.2%)
Metabolism and nutrition disorders
Anorexia	4/63 (6.3%)		0/62 (0%)
Hunger	2/63 (3.2%)		0/62 (0%)
Musculoskeletal and connective tissue disorders
Arthralgia	0/63 (0%)		2/62 (3.2%)
Nervous system disorders
Dizziness	18/63 (28.6%)		9/62 (14.5%)
Headache NOS	6/63 (9.5%)		9/62 (14.5%)
Somnolence	4/63 (6.3%)		0/62 (0%)
Disturbance in attention	3/63 (4.8%)		0/62 (0%)
Memory impairment	3/63 (4.8%)		0/62 (0%)
Hypoaesthesia	0/63 (0%)		3/62 (4.8%)
Psychiatric disorders
Agitation	2/63 (3.2%)		0/62 (0%)
Euphoric Mood	2/63 (3.2%)		0/62 (0%)
Respiratory, thoracic and mediastinal disorders
Epistaxis	2/63 (3.2%)		0/62 (0%)
Pharyngitis	2/63 (3.2%)		2/62 (3.2%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.